



July 28, 2017

Ms. Gay Dodson, Executive Director
Texas State Board of Pharmacy
William P. Hobby Building
Tower 3, Suite 500
333 Guadalupe Street
Austin, TX 78701

Dear Ms. Dodson:

The purpose of this letter is to notify you that the U.S. Food and Drug Administration does not intend to take further action with regard to an inspection of a pharmacy licensed by the Texas Board of Pharmacy (BOP), Medicine Store Pharmacy, Inc. dba RXPress Pharmacy located at 1000 W Weatherford Street Fort Worth, TX 76102 (License #: 18669).

FDA inspected the firm from August 15, 2016, to August 24, 2016. The Texas BOP was informed of the inspection, but did not accompany FDA investigators during the inspection. No Form FDA 483 was issued to the firm at the close of this inspection.

During the inspection, the FDA investigators reviewed a small sample of records for products compounded by RXPress Pharmacy and determined, based on this sample, that this firm appeared to obtain valid prescriptions for individually-identified patients for the drug products that it compounded and distributed.

On January 18, 2017, FDA was informed by a representative of the Texas BOP that the firm closed on October 31, 2016, and transferred its records to Care Mart Pharmacy.

FDA does not intend to take further action with regard to the findings of this inspection. Please notify us if you become aware of any adverse events or product quality concerns associated with drugs made at this facility before it closed or if you observe any practices at this facility if it resumes operations that concern you or that could be violations of Federal law.

Page 2 – Ms. Gay Dodson, Executive Director
Texas State Board of Pharmacy
July 28, 2017

We look forward to continuing to work with you on the oversight of compounding pharmacies. If you have additional questions, please contact me at 214-253-5288.

Sincerely,

John W.
Diehl -S

Digitally signed by John W. Diehl -S
DN: c=US, o=U.S. Government,
ou=HHS, ou=FDA, ou=People,
cn=John W. Diehl -S,
0.9.2342.19200300.100.1.1=200009972
7
Date: 2017.07.28 12:27:08 -0500

John W. Diehl
Acting Director, Compliance Branch
Office of Pharmaceutical Quality Operations,
Division II